Marotta Cassandra, Gonzalez-Ortiz Fernando, Turton Michael, Zetterberg Henrik, Harrison Peter, Hovens Christopher M, Sinclair Benjamin, O'Brien Terence J, Blennow Kaj, Vivash Lucy
Department of Neuroscience School of Translational Medicine Monash University Melbourne Victoria Australia.
Department of Psychiatry and Neurochemistry Institute of Neuroscience and Physiology The Sahlgrenska Academy, University of Gothenburg Gothenburg Sweden.
Alzheimers Dement (Amst). 2025 Jun 5;17(2):e70123. doi: 10.1002/dad2.70123. eCollection 2025 Apr-Jun.
Brain-derived tau (BD-tau) measures tau specifically from brain-derived sources and can differentiate Alzheimer's disease (AD) from other diseases. This study investigated BD-tau as a potential biomarker of treatment effect.
BD-tau and phosphorylated tau-217 (p-tau217) levels were measured after treatment with an anti-tau drug in AD and behavioral variant frontotemporal dementia (bvFTD) clinical trials, and the association with total tau (t-tau), p-tau181 and amyloid beta 42 (Aβ42) was examined.
Cerebrospinal fluid (CSF) BD-tau decreased after treatment in the AD cohort; however, no change was seen in bvFTD or p-tau217 in either cohort. CSF t-tau and p-tau181 correlated with BD-tau in AD ( = 0.9113 and 0.7746, < 0.0001) and bvFTD ( = 1.0 and = 0.79, < 0.05). CSF BD-tau did not correlate with serum or plasma BD-tau in bvFTD.
CSF BD-tau shows potential as a biomarker of treatment effect in AD but not bvFTD. Further research is needed to investigate this effect in blood-based samples and in other neurodegenerative diseases. : ACTRN12611001200976, ACTRN12617001218381.
Cerebrospinal fluid (CSF) brain-derived tau (BD-tau) levels decreased with sodium selenate treatment in patients with Alzheimer's disease (AD).CSF BD-tau levels did not change with sodium selenate treatment in bvFTD.Baseline CSF BD-tau correlated with CSF total tau (t-tau) and phosphorylated tau-181 (p-tau181) in AD and behavioral variant frontotemporal dementia (bvFTD).Baseline serum and plasma BD-tau levels did not correlate with CSF BD-tau in bvFTD.CSF p-tau217 did not change with sodium selenate treatment in AD or bvFTD.
脑源性tau蛋白（BD-tau）专门检测源自脑源性的tau蛋白，可将阿尔茨海默病（AD）与其他疾病区分开来。本研究调查了BD-tau作为治疗效果潜在生物标志物的情况。
在AD和行为变异型额颞叶痴呆（bvFTD）的临床试验中，用抗tau药物治疗后测量BD-tau和磷酸化tau-217（p-tau217）水平，并检测其与总tau蛋白（t-tau）、p-tau181和淀粉样β蛋白42（Aβ42）的相关性。
AD队列治疗后脑脊液（CSF）中BD-tau降低；然而，bvFTD队列或两个队列中的p-tau217均未见变化。AD（r = 0.9113和0.7746，P < 0.0001）和bvFTD（r = 1.0和r = 0.79，P < 0.05）中，CSF t-tau和p-tau181与BD-tau相关。bvFTD中，CSF BD-tau与血清或血浆BD-tau不相关。
CSF BD-tau显示出作为AD而非bvFTD治疗效果生物标志物的潜力。需要进一步研究以调查基于血液的样本和其他神经退行性疾病中的这种效应。试验注册号：ACTRN12611001200976，ACTRN12617001218381。
阿尔茨海默病（AD）患者经亚硒酸钠治疗后，脑脊液（CSF）脑源性tau蛋白（BD-tau）水平降低。亚硒酸钠治疗后，bvFTD患者的CSF BD-tau水平未发生变化。AD和行为变异型额颞叶痴呆（bvFTD）中，基线CSF BD-tau与CSF总tau蛋白（t-tau）和磷酸化tau-181（p-tau181）相关。bvFTD中，基线血清和血浆BD-tau水平与CSF BD-tau不相关。AD或bvFTD患者经亚硒酸钠治疗后，CSF p-tau217未发生变化。
